Focused ultrasound for high-risk human papillomavirus infection-related low-grade cervical lesions: a prospective cohort study. (31st December 2022)

• Record Type: Journal Article
• Authors: Wang, Wenping; Yao, Yuqin; Liu, Yujuan; Ren, Jiaojiao; Chen, Liming; Wang, Zhibiao; Zhou, Honggui
• Is Part Of: International journal of hyperthermia. Volume 39:Number 1(2022)
• Page Start: 1327
• Page End: 1334
• Publication Date: 2022-12-31
• Subjects: Focused ultrasound -- high-risk human papillomavirus -- low-grade squamous intraepithelial lesion -- efficacy -- safety; Thermotherapy -- Periodicals; 615.832
• DOI: 10.1080/02656736.2022.2130443
• Languages: English
• ISSNs: 0265-6736

Abstract

Abstract: Objectives: To assess the efficacy and safety of focused ultrasound (FU) for high-risk human papillomavirus (HR-HPV) infection-related cervical low-grade squamous intraepithelial lesions (LSIL). Methods: Of 185 patients who met the inclusion criteria for this prospective study from October 2020 to November 2021, 95 received FU and 90 were followed up only. At the six-month follow-up, the HR-HPV clearance and LSIL regression rates of the groups were compared and factors affecting HR-HPV clearance were analyzed. The safety and side effects of FU were evaluated. Results: No significant difference was found in the baseline clinical data between the two groups ( p > 0.05). At the six-month follow-up, the HR-HPV clearance rates were 75.6% in the FU group and 25.6% in the observation group ( p = 0.000). The LSIL regression rates were 89.5% in the FU group and 56.4% in the observation group ( p = 0.000). Multivariate logistic regression analysis showed that the HR-HPV clearance rate in the FU group was 9.03 times higher than that in the observation group (95% confidence interval [CI], 3.75–21.73, p = 0.000), and the clearance rate of single-type HR-HPV infections was 5.28 times higher than that of multi-type infections (95% CI, 1.83–15.23, p = 0.002). The mean intraoperative bleeding was 1.8 ± 0.6 (1–3) mL; the mean intraoperative pain score was 2.6 ± 1.0 (1–6). Conclusions: For patients with HR-HPV infection-related histological LSIL, FU can eliminate HR-HPV infection and cause lesions to regress in a short time, with few adverse effects and good tolerance.